Copyright
©The Author(s) 2017.
World J Clin Oncol. Feb 10, 2017; 8(1): 1-20
Published online Feb 10, 2017. doi: 10.5306/wjco.v8.i1.1
Published online Feb 10, 2017. doi: 10.5306/wjco.v8.i1.1
Table 1 Prospective trials of multi-modality therapy for resectable stage III non-small-cell lung cancer
| Ref. | Phase | Study design | Chemo regimen | RT | Number of patients | Stage | Median f/u (mo) | OS | Median OS (mo) | PFS | Median PFS (mo) | Response rate |
| Pless et al[35] (2015) | Induction chemoRT + surgery vs induction chemo + surgery | Cisplatin/docetaxel | 44 Gy in 2 Gy fxns over 3 wk | 232 | IIIA (N2) | 52.4 | 37.1 vs 26.2 | 12.8 vs 11.6 (P = 0.67) | ORR: 61% vs 44% | |||
| Thomas et al[36] (2008) | 3 | Induction chemo + induction chemoRT + surgery vs induction chemo + surgery | Induction: Cisplatin/etoposide ChemoRT: Carboplatin/vinorelbine | 45 Gy in 1.5 Gy fxns (twice daily) | 524 | III A/B (N2/3) | 5-yr, 21% vs 18% (P = 0.97) | 15.7 mo vs 17.6 mo | 5-yr, 16% vs 14% (P = 0.87) | 9.5 vs 10 | CR: 60% vs 20% (P < 0.0001) Mediastinal downstaging: 46% vs 29% (P < 0.02) | |
| EORTC 08941 Van Meerbeeck et al[37] (2007) | 3 | Induction chemo + surgery vs chemoRT | Platinum-based | 60-62.5 Gy in 1.95-2.05 Gy daily fxns | 332 | IIIA (N2) | > 72 | 5-yr, 15.7% vs 14% (P = 0.6) | 16.4 vs 17.5 (P = 0.6) | 2-yr, 27% vs 24% (P = 0.6) | 9 vs 11.3 (P = 0.6) | |
| INT 0139 Albain et al[38] (2009) | 3 | Induction chemoRT + surgery vs chemoRT | Cisplatin/etoposide | 45 Gy boost to 61 Gy if definitive chemoRT | 396 | IIIA (N2) | 22.5 | 5-yr, 27.2% vs 20.3% (P = 0.10) | 23.6 vs 22.2 (P = 0.24) | 5-yr, 22.4% vs 11.1% (P = 0.017) | 12.8 vs 10.5 (P = 0.017) | |
| RTOG 0229 Suntharalingam et al[39] (2010) | 2 | Induction chemoRT + surgery | Carboplatin/paclitaxel | 50.4 Gy + 10.8 Gy to gross disease | 60 | III A/B (N2/3) | 1-yr, 77% | 26.6 | 1-yr, 52% | 13.1 | Improved mediastinal sterilization 50% to 70% met | |
| ESPATUE Eberhardt et al[40] (2015) | 3 | Induction chemotherapy + induction chemoRT + RT boost vs Induction chemotherapy + induction chemoRT + surgery | Induction chemo: Cisplatin/paclitaxel Induction chemoRT: Cisplatin/vinorelbine | 45 Gy in 1.5 Gy twice daily fxns Definitive chemoRT: Boost to 65-71 Gy | 246 | III A/B (N2/N3) | 78 | 5-yr, 40% vs 44% (P = 0.34) | 5-yr PFS, 35% vs 32% (P = 0.75) | |||
| Eberhardt et al[40] (2015) | 3 | Induction chemo + induction chemoRT + surgery vs induction chemo + definitive chemoRT | Induction: Cisplatin/paclitaxel ChemoRT: cisplatin/vinorelbine | 45 Gy in 1.5 Gy fxns (twice daily) | 246 | IIIA (N2), select IIIB (N3) | 78 | 5-yr, 40% vs 44% | 5-yr, 35% vs 32% |
- Citation: Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8(1): 1-20
- URL: https://www.wjgnet.com/2218-4333/full/v8/i1/1.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i1.1